Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
2401-2420 of 3,900 trials

Immunotherapy for Advanced Cancer: Standard vs. Reduced Dose

We are comparing standard immunotherapy treatment with a less frequent dosing schedule for patients with advanced cancer. The goal is to see if the reduced dose is just as effective and to evaluate its impact on quality of life and safety.

Advanced or Metastatic Cancer>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesOncology

Atrial Fibrillation: Dapagliflozin Treatment Study

We are investigating if dapagliflozin can help prevent the return of atrial fibrillation after cardioversion compared to usual care. This study aims to see how well it works in prolonging the time before atrial fibrillation recurs.

Atrial Fibrillation≤3 monthsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine

Triple-Negative Breast Cancer: Ceralasertib with Durvalumab and Nab-Paclitaxel

We are studying a new treatment approach for patients with advanced triple-negative breast cancer who have relapsed after prior therapies. This trial aims to see if combining ceralasertib with other medications can improve their response to treatment.

Advanced Triple Negative Breast Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Metastatic Colorectal Cancer: Trifluridine/Tipiracil with Panitumumab vs. Bevacizumab

We are studying two treatment combinations to find out which one works better for people with metastatic colorectal cancer. The trial also looks at safety and how treatments affect patients' quality of life.

Metastatic Colorectal Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteOncology

Intrahepatic Cholangiocarcinoma: PUMP IV Trial

We are studying a new chemotherapy method to help prevent liver cancer from coming back after surgery. This trial will also look at side effects and how it affects patients' quality of life.

Intrahepatic Cholangiocarcinoma3-6 monthsEfficacy phase (II)6-10 visitsCost ReimbursementGastroenterologyHepatologyOncology

Angiosarcoma and Undifferentiated Pleomorphic Sarcoma: Propranolol and Pembrolizumab Study

We are studying the effects of a new treatment combining propranolol and pembrolizumab for patients with advanced Angiosarcoma and Undifferentiated Pleomorphic Sarcoma. The goal is to see if this combination improves survival and quality of life.

Advanced Angiosarcoma and Undifferentiated Pleomorphic Sarcoma3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Prostate Cancer: 225Ac-PSMA I&T Treatment

We are testing a new radioactive treatment for men with prostate cancer. This study aims to evaluate its safety and how well it works.

Metastatic Prostate Cancer>2 yearsSafety phase (I)Oncology

Breast Cancer Prevention: Denosumab for Women with BRCA1 Mutation

We are studying whether Denosumab can help prevent breast cancer in women carrying a BRCA1 mutation. This trial compares its effects to a placebo to see if it reduces cancer risk.

Breast Cancer Prevention in BRCA1 Mutation Carriers>2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesPartially RemoteHematologyOncology

IDH1/IDH2-Mutant Glioma: Vorasidenib with Temozolomide

We are studying the safety and effectiveness of a new drug, vorasidenib, combined with temozolomide for patients with IDH1- or IDH2-mutant gliomas. This research aims to see if this combination can improve treatment outcomes.

IDH1-mutant GliomaIDH2-mutant Glioma>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Sickle Cell Disease: Hydroxycarbamide Tablets for Children

We are studying the effects of a twice-daily dose of Hydroxycarbamide in children with sickle cell disease. This trial aims to evaluate its safety, effectiveness, and how well children tolerate the treatment.

Sickle Cell Disease>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyPediatrics

Cystic Fibrosis: VX-121/Tezacaftor/Deutivacaftor Therapy

We are studying a new combination therapy for children with cystic fibrosis to evaluate its safety and how well it works. This trial focuses on kids aged 1 to 11 years.

Cystic Fibrosis6-12 monthsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicinePulmonology

Karonudib for Blood Cancers: Phase 1 Study

We are evaluating the safety and tolerability of Karonudib in patients with advanced blood cancers like Acute Myeloid Leukemia and Multiple Myeloma. This study aims to find the best dose and understand how well it works with other cancer treatments.

Blood Cancers>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

Kidney Transplant: Eight Treg Immunotherapy

We are testing a new treatment using expanded regulatory T cells for living donor kidney transplant recipients. The goal is to see if this approach is safe and may reduce the need for traditional immunosuppressive medications.

Chronic Kidney FailureSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesInternal MedicineNephrology

Rare Cancers: Targeted Drug Study

We are exploring how well existing targeted cancer drugs work for patients with rare and hard-to-treat cancers. The study will also look at any serious side effects from these treatments.

Cancer>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Knee Surgery Pain Relief: Nefopam Study

We are investigating whether an oral medication called nefopam can reduce morphine use after total knee replacement surgery. This study aims to improve pain management for adults recovering from this procedure.

Postoperative Pain After Knee Surgery>2 yearsSafety phase (I)Efficacy phase (II)Investigational MedicinesInternal MedicineOrthopedics and Traumatology

Esophageal Cancer: Trastuzumab and Pertuzumab Study

We are studying if adding trastuzumab and pertuzumab to standard treatment helps improve survival for patients with HER2 positive esophageal adenocarcinoma. This trial involves patients whose cancer can be surgically removed.

HER2 Positive Esophageal Adenocarcinoma3-6 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesOncology

Acute Myocarditis: Ibuprofen vs. Standard Pain Relief

We are studying whether ibuprofen can better improve heart health compared to regular pain relief in patients with acute myocarditis. This trial focuses on how these treatments affect heart imaging results after six months.

Acute Myocarditis>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCardiologyInternal Medicine

Endurance Performance: Pseudoephedrine Study

We are investigating how a full dose of pseudoephedrine affects cycling performance in trained athletes after a tough race simulation. The study also looks at the right dosage and the body's response to it.

Healthy Volunteers6-12 monthsMonitoring phase (IV)Investigational MedicinesInternal MedicinePediatrics

Cardiogenic Shock: Levosimendan vs. Placebo

We are studying whether early use of levosimendan can improve health outcomes in patients with cardiogenic shock compared to a placebo. The goal is to see if it reduces the need for life support and improves survival rates.

Cardiogenic Shock>2 yearsConfirmation phase (III)Investigational MedicinesPartially RemoteCardiologyInternal Medicine

Kidney Transplant Rejection: Everolimus Study

We are studying whether everolimus can help kidney transplant patients with a specific type of rejection maintain kidney function and reduce damage. This trial looks at its effects over six months.

Kidney Failure6-12 monthsMonitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesNephrology